pravastatin has been researched along with glyburide in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| Ishikawa, K; Kawabata, H; Ryomoto, T | 1 |
| Ilkay Alp, F; Kaleli, D; Ozdemir, O; Sönmez Uydeş-Doğan, B; Takir, S; Topal, G | 1 |
| Chang, NC; Lee, TM; Lin, MS; Tsai, CH | 2 |
| Chang, NC; Lee, TM; Lin, MS | 1 |
2 review(s) available for pravastatin and glyburide
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pravastatin and glyburide
| Article | Year |
|---|---|
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
16 other study(ies) available for pravastatin and glyburide
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts.
Topics: Adenosine Triphosphate; Animals; Enzyme Inhibitors; Glyburide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; In Vitro Techniques; Magnetic Resonance Spectroscopy; Myocardial Ischemia; Myocardium; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphorus Isotopes; Potassium Channels; Pravastatin; Rabbits | 2001 |
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Glyburide; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Nitroarginine; Ouabain; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilation | 2005 |
Effect of pravastatin on left ventricular mass in the two-kidney, one-clip hypertensive rats.
Topics: Animals; Anti-Arrhythmia Agents; Atrial Natriuretic Factor; Echocardiography; Gene Expression Regulation; Glyburide; Heart Ventricles; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Hypertrophy, Left Ventricular; Male; Nicorandil; Potassium Channels; Pravastatin; Rats; Rats, Wistar; Vasodilator Agents | 2006 |
Effects of pravastatin on ventricular remodeling by activation of myocardial KATP channels in infarcted rats: role of 70-kDa S6 kinase.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Electrophysiology; Glyburide; Heart; Immunohistochemistry; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Polymerase Chain Reaction; Potassium Channels; Pravastatin; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases, 70-kDa; Ventricular Remodeling | 2007 |
Effect of pravastatin on sympathetic reinnervation in postinfarcted rats.
Topics: Animals; Blotting, Western; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; GAP-43 Protein; Glyburide; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; KATP Channels; Ligation; Male; Myocardial Infarction; Myocardium; Neurofilament Proteins; Nicorandil; Norepinephrine; Pinacidil; Polymerase Chain Reaction; Potassium Channel Blockers; Pravastatin; Rats; Rats, Wistar; RNA, Messenger; Sympathetic Nervous System; Tachycardia, Ventricular; Time Factors; Tyrosine 3-Monooxygenase; Ventricular Fibrillation; Ventricular Remodeling | 2007 |